5505-16-8

Basic information

• Product Name: 3,5-diamino-2,4,6-triiodobenzoic acid
• Synonyms: 3,5-diamino-2,4,6-triiodobenzoic acid;3,5-Diamino-2,4,6-Triidobenzoicacid;3,5-diamino-2,4,6-triiodobenzoate;3,5-DIAMINO-2,4-TRIIODOBENZOIC ACID
• CAS NO: 5505-16-8
• Molecular Formula: C₇H₅I₃N₂O₂
• Molecular Weight: 529.84021
• EINECS: 226-845-7
• Product Categories: Amines;Aromatics;Metabolites & Impurities
• Mol File: 5505-16-8.mol

Chemical Properties

• Melting Point: 154-158 °C (decomp)
• Boiling Point: 503.9°Cat760mmHg
• Flash Point: 258.6°C
• Appearance: /
• Density: 3.067g/cm³
• Vapor Pressure: 5.62E-11mmHg at 25°C
• Storage Temp.: Refrigerator
• Solubility: Chloroform, Dichloromethane, DMSO (Slightly), Methanol (Slightly)
• PKA: 1.66±0.10(Predicted)
• CAS DataBase Reference: 3,5-diamino-2,4,6-triiodobenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-diamino-2,4,6-triiodobenzoic acid(5505-16-8)
• EPA Substance Registry System: 3,5-diamino-2,4,6-triiodobenzoic acid(5505-16-8)

Safety Data

• Hazardous Substances Data: 5505-16-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3,5-Diamino-2,4,6-triiodobenzoic acid is used as a chemical intermediate for the development of pharmaceutical products, particularly those aimed at addressing conditions related to its mutagenic and cytotoxic properties. Its role in the pharmaceutical industry is crucial for the synthesis of drugs that can potentially target specific biological pathways affected by its parent compound, Diatrizoate.
Used in Research and Development:
In the field of research and development, 3,5-diamino-2,4,6-triiodobenzoic acid serves as a valuable compound for studying the effects of Diatrizoate and its metabolites on cellular processes. Its mutagenic and cytotoxic properties make it an important subject for understanding the mechanisms of action and potential risks associated with exposure to Diatrizoate, which can inform the development of safer alternatives or mitigation strategies.
Used in Toxicology Studies:
3,5-Diamino-2,4,6-triiodobenzoic acid is utilized in toxicology studies to evaluate the potential hazards and risks associated with exposure to Diatrizoate. By examining the effects of this metabolite on cellular structures and functions, researchers can gain insights into the toxicological profile of Diatrizoate and develop appropriate safety measures and guidelines for its use in medical applications.
Used in Environmental Monitoring:
As a metabolite of Diatrizoate, 3,5-diamino-2,4,6-triiodobenzoic acid can be found in various environmental matrices, such as water and soil. It is used in environmental monitoring programs to assess the presence and concentration of Diatrizoate and its metabolites in the environment, which can help in understanding the potential ecological impacts and inform strategies for environmental protection and remediation.

InChI:InChI=1/C7H5I3N2O2.Na/c8-2-1(7(13)14)3(9)6(12)4(10)5(2)11;/h11-12H2,(H,13,14);/q;+1/p-1

Upstream product

• 535-87-5 3.5-diaminobenzoic acid 
• 737-31-5 sodium diatrizoate 

Downstream Products

• 67032-30-8 3,5-bis-butyrylamino-2,4,6-triiodo-benzoic acid 
• 115051-97-3 3,5-bis-heptanoylamino-2,4,6-triiodo-benzoic acid 
• 67049-60-9 2,4,6-triiodo-3,5-bis-valerylamino-benzoic acid 
• 67032-31-9 3,5-bis-hexanoylamino-2,4,6-triiodo-benzoic acid 
• 117-96-4 diatrizoic acid 
• 85-16-5 2,4,6-triiodo-3,5-bis-propionylamino-benzoic acid 
• 67031-62-3 3,5-bis-formylamino-2,4,6-triiodo-benzoic acid 
• 25883-07-2 3,5-bis(4-carboxybutyramido)-2,4,6-triiodobenzoic acid 
• 267000-21-5 3,5-diformylamido-2,4,6-triiodo-benzoic acid chloride 

Relevant articles and documents

A comparative study between three stability indicating spectrophotometric methods for the determination of diatrizoate sodium in presence of its cytotoxic degradation product based on two-wavelength selection

Abstract Three sensitive, selective, and precise stability indicating spectrophotometric methods for the determination of the X-ray contrast agent, diatrizoate sodium (DTA) in the presence of its acidic degradation product (highly cytotoxic 3,5-diamino metabolite) and in pharmaceutical formulation, were developed and validated. The first method is ratio difference, the second one is the bivariate method, and the third one is the dual wavelength method. The calibration curves for the three proposed methods are linear over a concentration range of 2-24 μg/mL. The selectivity of the proposed methods was tested using laboratory prepared mixtures. The proposed methods have been successfully applied to the analysis of DTA in pharmaceutical dosage forms without interference from other dosage form additives. The results were statistically compared with the official US pharmacopeial method. No significant difference for either accuracy or precision was observed.

Stability indicating spectrophotometric and spectrodensitometric methods for the determination of diatrizoate sodium in presence of its degradation product

Three sensitive, selective, and precise stability indicating methods for the determination of the X-ray contrast agent, diatrizoate sodium (DTA), in the presence of its acidic degradation product (highly cytotoxic 3,5 diamino metabolite) and in pharmaceutical formulation were developed and validated. The first method is a first derivative (D1) spectrophotometric one, which allows the determination of DTA in the presence of its degradate at 231.2 nm (corresponding to zero crossing of the degradate) over a concentration range of 2-24 μg/mL with mean percentage recovery 99.95 ± 0.97%. The second method is the first derivative of the ratio spectra (DD1) by measuring the peak amplitude at 227 nm over the same concentration range as D1 spectrophotometric method, with mean percentage recovery 99.99 ± 1.15%. The third method is a TLC-densitometric one, where DTA was separated from its degradate on silica gel plates using chloroform:methanol:ammonium hydroxide (20:10:2 by volume) as a developing system. This method depends on quantitative densitometric evaluation of thin layer chromatogram of DTA at 238 nm over a concentration range of 4-20 μg/spot, with mean percentage recovery 99.88 ± 0.89%. The selectivity of the proposed methods was tested using laboratory-prepared mixtures. The proposed methods have been successfully applied to the analysis of DTA in pharmaceutical dosage forms without interference from other dosage form additives. The results were statistically compared with the official US pharmacopeial method. No significant difference for either accuracy or precision was observed.

Synthesis and evaluation of potential CT (computer tomography) contrast agents for bone structure and microdamage analysis

The design and synthesis of several novel X-ray contrast agents 1-3, developed for targeting bone structures, and in particularly microcracks in bones, using CT (Computer Tomography) detection is described. These contrast agents are based on the use of the well known triiodobenzene platform, which was conjugated into one or more phenyliminodiacetate moieties, which can be used to 'lock' onto bone matrices. Compounds 1-3 were all tested for their ability to visualise cracks in bone structures (bovine bones) using μ-CT imaging. The Royal Society of Chemistry 2006.